德语D-A-CH国家核医学和放射药学的回旋加速器:现状和趋势的更新

Claus Zippel, Johannes Ermert, Marianne Patt, Franz Josef Gildehaus, Tobias L Ross, Gerald Reischl, Torsten Kuwert, Christoph Solbach, Bernd Neumaier, Oliver Kiss, Markus Mitterhauser, Wolfgang Wadsak, Roger Schibli, Klaus Kopka
{"title":"德语D-A-CH国家核医学和放射药学的回旋加速器:现状和趋势的更新","authors":"Claus Zippel, Johannes Ermert, Marianne Patt, Franz Josef Gildehaus, Tobias L Ross, Gerald Reischl, Torsten Kuwert, Christoph Solbach, Bernd Neumaier, Oliver Kiss, Markus Mitterhauser, Wolfgang Wadsak, Roger Schibli, Klaus Kopka","doi":"10.3389/fnume.2022.850414","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cyclotrons form a central infrastructure and are a resource of medical radionuclides for the development of new radiotracers as well as the production and supply of clinically established radiopharmaceuticals for patient care in nuclear medicine.</p><p><strong>Aim: </strong>To provide an updated overview of the number and characteristics of cyclotrons that are currently in use within radiopharmaceutical sciences and for the development of radiopharmaceuticals to be used for patient care in Nuclear Medicine in Germany (D), Austria (A) and Switzerland (CH).</p><p><strong>Methods: </strong>Publicly available information on the cyclotron infrastructure was (i) consolidated and updated, (ii) supplemented by selective desktop research and, last but not least, (iii) validated by members of the committee of the academic \"Working Group Radiochemistry and Radiopharmacy\" (AGRR), consisting of radiochemists and radiopharmacists of the D-A-CH countries and belonging to the German Society of Nuclear Medicine (DGN), as well as the Radiopharmaceuticals Committee of the DGN.</p><p><strong>Results: </strong>In total, 42 cyclotrons were identified that are currently being operated for medical radionuclide production for imaging and therapy in Nuclear Medicine clinics, 32 of them in Germany, 4 in Austria and 6 in Switzerland. Two thirds of the cyclotrons reported (67%) are operated by universities, university hospitals or research institutions close to a university hospital, less by/in cooperation with industrial partners (29%) or a non-academic clinic/ PET-center (5%). Most of the cyclotrons (88%) are running with up to 18 MeV proton beams, which is sufficient for the production of the currently most common cyclotron-based radionuclides for PET imaging.</p><p><strong>Discussion: </strong>The data presented provide an academically-updated overview of the medical cyclotrons operated for the production of radiopharmaceuticals and their use in Nuclear Medicine in the D-A-CH countries. In this context, we discuss current developments and trends with a view to the cyclotron infrastructure in these countries, with a specific focus on organizational aspects.</p>","PeriodicalId":73095,"journal":{"name":"Frontiers in nuclear medicine (Lausanne, Switzerland)","volume":" ","pages":"850414"},"PeriodicalIF":0.0000,"publicationDate":"2022-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440920/pdf/","citationCount":"0","resultStr":"{\"title\":\"Cyclotrons Operated for Nuclear Medicine and Radiopharmacy in the German Speaking D-A-CH Countries: An Update on Current Status and Trends.\",\"authors\":\"Claus Zippel, Johannes Ermert, Marianne Patt, Franz Josef Gildehaus, Tobias L Ross, Gerald Reischl, Torsten Kuwert, Christoph Solbach, Bernd Neumaier, Oliver Kiss, Markus Mitterhauser, Wolfgang Wadsak, Roger Schibli, Klaus Kopka\",\"doi\":\"10.3389/fnume.2022.850414\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Cyclotrons form a central infrastructure and are a resource of medical radionuclides for the development of new radiotracers as well as the production and supply of clinically established radiopharmaceuticals for patient care in nuclear medicine.</p><p><strong>Aim: </strong>To provide an updated overview of the number and characteristics of cyclotrons that are currently in use within radiopharmaceutical sciences and for the development of radiopharmaceuticals to be used for patient care in Nuclear Medicine in Germany (D), Austria (A) and Switzerland (CH).</p><p><strong>Methods: </strong>Publicly available information on the cyclotron infrastructure was (i) consolidated and updated, (ii) supplemented by selective desktop research and, last but not least, (iii) validated by members of the committee of the academic \\\"Working Group Radiochemistry and Radiopharmacy\\\" (AGRR), consisting of radiochemists and radiopharmacists of the D-A-CH countries and belonging to the German Society of Nuclear Medicine (DGN), as well as the Radiopharmaceuticals Committee of the DGN.</p><p><strong>Results: </strong>In total, 42 cyclotrons were identified that are currently being operated for medical radionuclide production for imaging and therapy in Nuclear Medicine clinics, 32 of them in Germany, 4 in Austria and 6 in Switzerland. Two thirds of the cyclotrons reported (67%) are operated by universities, university hospitals or research institutions close to a university hospital, less by/in cooperation with industrial partners (29%) or a non-academic clinic/ PET-center (5%). Most of the cyclotrons (88%) are running with up to 18 MeV proton beams, which is sufficient for the production of the currently most common cyclotron-based radionuclides for PET imaging.</p><p><strong>Discussion: </strong>The data presented provide an academically-updated overview of the medical cyclotrons operated for the production of radiopharmaceuticals and their use in Nuclear Medicine in the D-A-CH countries. In this context, we discuss current developments and trends with a view to the cyclotron infrastructure in these countries, with a specific focus on organizational aspects.</p>\",\"PeriodicalId\":73095,\"journal\":{\"name\":\"Frontiers in nuclear medicine (Lausanne, Switzerland)\",\"volume\":\" \",\"pages\":\"850414\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-04-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440920/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in nuclear medicine (Lausanne, Switzerland)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3389/fnume.2022.850414\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in nuclear medicine (Lausanne, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fnume.2022.850414","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

回旋加速器是一种中心基础设施,是一种医用放射性核素资源,可用于开发新的放射性示踪剂,以及生产和供应临床确定的用于核医学患者护理的放射性药物。目的提供目前在放射性药物科学中使用的回旋加速器的数量和特征的最新概述,以及用于德国(D),奥地利(A)和瑞士(CH)核医学患者护理的放射性药物的开发。方法对回旋加速器基础设施的公开可用信息进行(i)整合和更新,(ii)通过选择性桌面研究补充,最后但并非最不重要的是,(iii)由“放射化学和放射药学工作组”(AGRR)学术委员会成员进行验证,该工作组由D-A-CH国家的放射化学家和放射药理学家组成,属于德国核医学学会(DGN),以及DGN的放射性药物委员会。结果共确定了42台回旋加速器,目前正在核医学诊所用于成像和治疗的医用放射性核素生产,其中32台在德国,4台在奥地利,6台在瑞士。报告的回旋加速器中有三分之二(67%)由大学、大学医院或靠近大学医院的研究机构操作,较少由工业伙伴(29%)或非学术诊所/ pet中心(5%)操作。大多数回旋加速器(88%)以高达18mev的质子束运行,这足以生产目前最常见的用于PET成像的基于回旋加速器的放射性核素。所提供的数据提供了D-A-CH国家用于生产放射性药物的医用回旋加速器及其在核医学中的应用的最新学术概况。在此背景下,我们讨论当前的发展和趋势,着眼于这些国家的回旋加速器基础设施,特别关注组织方面。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Cyclotrons Operated for Nuclear Medicine and Radiopharmacy in the German Speaking D-A-CH Countries: An Update on Current Status and Trends.

Background: Cyclotrons form a central infrastructure and are a resource of medical radionuclides for the development of new radiotracers as well as the production and supply of clinically established radiopharmaceuticals for patient care in nuclear medicine.

Aim: To provide an updated overview of the number and characteristics of cyclotrons that are currently in use within radiopharmaceutical sciences and for the development of radiopharmaceuticals to be used for patient care in Nuclear Medicine in Germany (D), Austria (A) and Switzerland (CH).

Methods: Publicly available information on the cyclotron infrastructure was (i) consolidated and updated, (ii) supplemented by selective desktop research and, last but not least, (iii) validated by members of the committee of the academic "Working Group Radiochemistry and Radiopharmacy" (AGRR), consisting of radiochemists and radiopharmacists of the D-A-CH countries and belonging to the German Society of Nuclear Medicine (DGN), as well as the Radiopharmaceuticals Committee of the DGN.

Results: In total, 42 cyclotrons were identified that are currently being operated for medical radionuclide production for imaging and therapy in Nuclear Medicine clinics, 32 of them in Germany, 4 in Austria and 6 in Switzerland. Two thirds of the cyclotrons reported (67%) are operated by universities, university hospitals or research institutions close to a university hospital, less by/in cooperation with industrial partners (29%) or a non-academic clinic/ PET-center (5%). Most of the cyclotrons (88%) are running with up to 18 MeV proton beams, which is sufficient for the production of the currently most common cyclotron-based radionuclides for PET imaging.

Discussion: The data presented provide an academically-updated overview of the medical cyclotrons operated for the production of radiopharmaceuticals and their use in Nuclear Medicine in the D-A-CH countries. In this context, we discuss current developments and trends with a view to the cyclotron infrastructure in these countries, with a specific focus on organizational aspects.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.90
自引率
0.00%
发文量
0
期刊最新文献
Immunohistochemical basis for FAP as a candidate theranostic target across a broad range of cholangiocarcinoma subtypes. SMART-PET: a Self-SiMilARiTy-aware generative adversarial framework for reconstructing low-count [18F]-FDG-PET brain imaging. Editorial: Recent advances in radiotheranostics. αvβ6-integrin targeted PET/CT imaging in pancreatic cancer patients using 68Ga-Trivehexin. Contrastive learning for neural fingerprinting from limited neuroimaging data.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1